Aldeyra TherapeuticsFRA:137 +1.29%29 Quick Ratio is 2.72 as of Mar. 2026, which is 75% below its 10-year median of 10.72. GuruFocus rates FRA:137 with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Aldeyra Therapeutics ranks worse than 58.4% on this metric.
Aldeyra Therapeutics has a quick ratio of 2.72. It generally indicates good short-term financial strength.
The historical rank and industry rank for Aldeyra Therapeutics's Quick Ratio or its related term are showing as below:
FRA:137'
s Quick Ratio Range Over the Past 10 Years
Min: 2.58 Med: 10.72 Max: 34.59
Current: 2.72
During the past 13 years, Aldeyra Therapeutics's highest Quick Ratio was 34.59. The lowest was 2.58. And the median was 10.72.
FRA:137's Quick Ratio is ranked worse than 58.4% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:137: 2.72
Aldeyra Therapeutics (FRA:137) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Aldeyra Therapeutics Quick Ratio Related Terms
Aldeyra Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Aldeyra Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:137 vs CGTX, RANI, PEPG: Quick Ratio Comparison
For the Biotechnology subindustry, Aldeyra Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aldeyra Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Aldeyra Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Aldeyra Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aldeyra Therapeutics (FRA:137) has a Quick Ratio of 2.72 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Aldeyra Therapeutics and its competitors. This is 75% below median its historical median of 10.72. Over the past decade, Aldeyra Therapeutics' Quick Ratio has ranged from 2.58 to 34.59. According to the industry distribution chart, Aldeyra Therapeutics ranks #827 out of 1416 companies in the Biotechnology industry, placing it in the top 58.4%.
Is Aldeyra Therapeutics' Quick Ratio too high?
Aldeyra Therapeutics' current Quick Ratio of 2.72 is 75% below median its 10-year median of 10.72. Over the past 10 years, this metric has ranged from a low of 2.58 to a high of 34.59. The Biotechnology industry median Quick Ratio is 3.60. Aldeyra Therapeutics' value of 2.72 is 24.4% below this industry median. Based on the distribution chart, Aldeyra Therapeutics ranks #827 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' Quick Ratio compare to CGTX and RANI?
According to the Biotechnology industry distribution chart, Aldeyra Therapeutics ranks #827 out of 1416 companies for Quick Ratio. This places Aldeyra Therapeutics in the lower half of its industry. The industry median Quick Ratio is 3.60. Aldeyra Therapeutics' value of 2.72 is 24.4% below this benchmark. Historically, Aldeyra Therapeutics' own Quick Ratio has ranged from 2.58 to 34.59 over the past decade. While the company's 10-year median is 10.72 vs. the industry median of 3.60, Aldeyra Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aldeyra Therapeutics's current Quick Ratio of 2.72 is 24.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Aldeyra Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aldeyra Therapeutics's current Quick Ratio is 2.72, which is 75% below median its own 10-year median of 10.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (FRA:137) has a current Quick Ratio of 2.72. The current Quick Ratio is 2.72, which is 75% below median its 10-year median of 10.72 and 24.4% below the Biotechnology industry median of 3.60. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Aldeyra Therapeutics (FRA:137), the current Quick Ratio is 2.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score
Get the complete analysis for FRA:137
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:137 has been successfully added to your 
